In vivo and in vitro effects of amino-acid-based and bicarbonate-buffered peritoneal dialysis solutions with regard to peritoneal transport and cytokines/prostanoids dialysate concentrations

Nephrology Dialysis Transplantation

Volumn 12, Issue 8, 1997, Pages 1652-1660

  Plum, J ^a   Fussholler A ^a   Schoenicke, G ^a   Busch, T ^a   Erren, C ^a   Fieseler, C ^a   Kirchgessner J ^a   Passlick Deetjen, J ^a   Grabensee, B ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Bicarbonate; Cytokines; Lactate; Peritoneal dialysis fluids; Peritoneal transport; Prostanoids

Indexed keywords

6 OXOPROSTAGLANDIN F1 ALPHA; AMINO ACID; BICARBONATE; BUFFER; CREATININE; CYTOKINE; INTERLEUKIN 6; INTERLEUKIN 8; LACTIC ACID; PERITONEAL DIALYSIS FLUID; PROSTAGLANDIN E2; PROSTANOID; TUMOR NECROSIS FACTOR ALPHA; UREA;

ADULT; ARTICLE; BIOCOMPATIBILITY; BLOOD LEVEL; CELL MEMBRANE PERMEABILITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; CONTROLLED CLINICAL TRIAL; CREATININE BLOOD LEVEL; CROSSOVER PROCEDURE; DIALYSATE; DRUG CLEARANCE; FEMALE; HUMAN; HUMAN CELL; MALE; MONOCYTE; PERITONEUM CELL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; UREA BLOOD LEVEL;

ADULT; AMINO ACIDS; BICARBONATES; BIOLOGICAL TRANSPORT; BUFFERS; CROSS-OVER STUDIES; CYTOKINES; DIALYSIS SOLUTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; OSMOLAR CONCENTRATION; PERITONEAL DIALYSIS; PERITONEUM; PERMEABILITY; PROSPECTIVE STUDIES; PROSTAGLANDINS;

EID: 0030741736     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/12.8.1652     Document Type: Article

References (42)

1. Duwe AK, Vas SI, Weatherhead JW. Effects of the composition of peritoneal dialysis fluid on chemoluminescence, phagocytosis and bacterial activity in vitro. Infect Immun 1981; 33: 130-135
2. Lindholm B, Norbeck HE. Serum lipids and lipoproteins during continuous ambulatory peritoneal dialysis. Acta Med Scand 1986; 220: 143-151
3. Young GA, Dibble JB, Taylor AE et al. A longitudinal study of the effects of amino acid-based CAPD fluid on amino acid retention and protein losses. Nephrol Dial Transplant 1989; 4: 900-905
4. Passlick-Deetjen J, Koch R, Grabensee B. High osmolar amino acid solutions. An alternative to glucose. Contrib Nephrol 1991; 89: 134-146
5. Topley N, Williams JD. Role of the peritoneal membrane in the control of inflammation in the peritoeal cavity. Kidney Int 1994; 46 [Supp.48]: 71-78
6. Topley N, Mackenzie R, Jörres A, Coles GA, Davies M, Williams JD. Cytokine networks in continuous ambulatory dialysis. Interaction of resident cells during inflammation in the peritoneal cavity. Peril Dial Int 1993; 13 [Supp.2]: 282-285
7. Liberek T, Topley N, Jörres A et al. Peritoneal dialysis fluid inhibition of neutrophil (PMN) respiratory burst activation is related to the lowering of intracellular pH. Nephron 1993; 65: 260-265
8. Brunkhorst R, Mahiout A. Pyruvate neutralizes peritoneal dialysate cytotoxicity. Maintained integrity and proliferation of cultured human mesothelial cells. Kidney Int 1995; 48: 177-181
9. Liberek T, Topley N, Jörres A, Coles GA, Gahl GM, Williams JD. Peritoneal dialysis fluid inhibition of phagocyte function. Effect of osmolality and glucose concentration. J Am Soc Nephrol 1993; 3: 1508-1515
10. Breborowicz A, Rodela H, Oreopoulos DG. Toxicity of osmotic solutes on human mesothelial cells in vitro. Kidney Int 1992; 41: 1280-1285
11. Schollmeyer P, Andre M, Bohler H, Dobos G, Steinhauer HB. Effect of peritoneal dialysis solution on peritoneal macrophages and polymorphonuclear granulocytes. Nieren-Hochdruckkr. 1994; 23 [Supp.2]: 96-99
12. Alobaidi HM, Coles GA, Davies M, Lloyd G. Host defence in continuous ambulatory peritoneal dialysis. The effect of the dialysate on phagocyte function. Nephrol Dial Transplant 1986; 1: 16-21
13. Topley N, Alobaidi HM, Coles GA, Davies M, Williams JD, Lloyd D. The effect of dialysate on peritoneal phagocyte oxidative metabolism. Kidney Int 1988; 34: 404-411
14. Jörres A, Jörres D, Topley N, Gahl GM, Mahiout A. Leukotriene release from peripheral and peritoneal leukocytes following exposure to peritoneal dialysis solutions. Nephrol Dial Transplant 1991; 6: 495-501
15. Jörres A, Topley N, Teenweg L, Müller C, Köttgen E, Gahl GM. Inhibition of cytokine synthesis by peritoneal dialysate persists throughout the CAPD cycle. Am J Nephrol 1992; 12: 80-85
16. Coene MC, Solheid C, Claeys M, Herman AG. Prostaglandin production by cultured mesothelial cells. Arch Int Pharmcodyn 1981; 249: 316-318
17. Topley N, Jörres A, Luttmann W et al. Human peritoneal mesothelial cells synthesize Il-6. Induction by Il-1β and TNFα. Kidney Int 1993; 43: 226-233
18. Betjes MGH, Tuk CW, Struijk DG et al. Interleukin-8 production by human peritoneal mesothelial cells in response to tumor necrosis facto a, interleukin-1 and medium conditioned by macrophages co-cultured with Staphylococcus epidermidis. J Infect Dis 1993; 168: 1202-1210
19. Wieslander AP, Nordin MK, Kjellstrand PTT, Boberg UC. Toxicity of peritoneal dialysis fluids on cultured fibroblasts L-929. Kidney int 1991; 44: 77-79
20. Breborowicz A, Martis L, Oreopoulos DG. Changed in biocompatibility of dialysis fluid during its dwell in the peritoneal cavity. Perit Dial Int 1995; 15: 152-157
21. Witowski J, Topley N, Jörres A, Liberek T, Coles GA, Williams JD. Effect of lactate buffered peritoneal mesothelial cell interleuken-6 and prostaglandin synthesis. Kidney Int 1994; 46: 282-293
22. Feriani M, Dissegna D, La Greca G, Passlick-Deetjen J. Short-term clinical study with bicarbonate-containing peritoneal dialysis solution. Perit Dial Int 1993; 13: 296-301
23. Dobos GJ, Böhler J, Kuhlmann J et al. Bicarbonate-based dialysis solution preserves granulocyte functions. Perit Dial Int 1994; 14(4): 366-370
24. Lindholm B, Werynski A, Bergström J. Peritoneal dialysis with amino acid solutions. Fluid and solute transport kinetics. Artif Organs 1988; 12: 2-10
25. Park MS, Heimbürger O, Bergström J, Waniewski J, Werynski A, Lindholm B. Peritoneal transport during dialysis with amino acid-based solutions. Peril Dial Int 1993; 13: 280-288
26. Steinhauer HB, Lubrich-Birkner I, Kluthe R, Hörl WH, Schollmeyer P. Amino acid dialysate stimulates peritoneal prostaglandine E2 generation in humans. Adv Perit Dial 1988; 4: 21-26
27. Steinhauer HB, Lubrich-Birkner I, Kluthe R, Baumann R, Schollmeyer P. Effect of amino acid based dialysis solution on peritoneal permeability and prostanoid generation in patients undergoing continuous ambulatory peritoneal dialysis. Am J Nephrol 1992; 12: 61-67
28. Douma CE, de Waart DR, Struijk DG, Krediet RT. Effect of amino acid based dialysate on peritoneal blood flow and permeability in stable CAPD patients, a potential role for nitric oxide? Clin Nephrol 1996; 45(5): 295-302
29. Schenk U, Kiefer T, Mettang T, Kuhlmann U, Passlick-Deetjen J. In vitro effects of amino-acid-based versus glucose-based continuous ambulatory peritoneal dialysis fluids on peritoneal macrophage function. Nephron 1995; 68(3): 338-346
30. Jörres A, Gahl GM, Ludat K, Frei U, Passlick-Deetjen J. In vitro biocompatibility assessment in Aminobic, a novel bicarbonate-buffered amino acid solution for CAPD. Perit Dial Int 1995; 15 [Suppl. 1] Abstract 78
31. Henderson LW, Nolph KD. Altered permeability of the peritoneal membrane after using hypertonic peritoneal dialysis fluid. J Clin Invest 1969; 48: 992-1001
32. Jörres A, Gahl GM, Topley N et al. In-vitro biocompatibility of alternative CAPD fluids, comparison of bicarbonate-buffered and glucose-polymer-based solutions. Nephrol Dial Transplant 1994; 9: 785-790
33. Topley N. What is the ideal technique for testing the biocompatibility of peritoneal dialysis solutions. Perit Dial Int 1995; 15; 205-209
34. Hansen MB, Nielsen SE, Berg K. Re-examination and further development of a precise and rapid dye method for measuring cell growth / cell kill. J Immunol Methods 1989; 119: 203
35. Bruno M, Bagnis C, Maragella M et al. CAPD with an amino acid dialysis solution: a long term cross-over study. Kidney Int 1989; 5: 1189-1194
36. Mican-JAM, Arora-N, Burd-PR, Metcalfe-DD. Passive cutaneous anaphylaxis in mouse skin is associated with local accumulation of interleukin-6 mRNA and immunoreactive interleukin-6 protein. J Allergy Clin Immunol 1992; 90(5): 815-824
37. Colletti LM, Burtch GD, Remick DG et al. The production of tumor necrosis factor alpha and the development of a pulmonary capillary injury following hepatic ischemia/reperfusion. Transplantation 1990; 49(2): 268-272
38. Labrid CL, Perdrix L. Mechanisms of oedema. Activity of Daflon 500mg. Phlebology. 1992; 7 [Supp.2]: 30-36
39. Zemel D, ten Berge RJ, Struijk DG, Bloemena E, Koomen GC, Krediet RT. Interleukin-6 in CAPD patients without peritonitis: relationship to the intrinsic permeability of the peritoneal membrane. Clin Nephrol 1992; 37(2): 97-103
40. Li FK, Loetscher P, Williams JD, Topley N. Mononuclear cells'(MNC) migration across human peritoneal mesothelial cell (HPMC) monolayer is dependent on the directed secretion of HPMC-derived MDP-1 and RANTES. Perit Dial Int 1996; 16 [Supp.2]: 42
41. Krane SM, Goldring MB. Potential role for interleukin-1 in fibrosis associated with chronic ambulatory peritoneal dialysis. Blood Purif 1988; 6/3: 173-177
42. Lee HG, Choi I, Pyun KH, Park KW. Peritoneal lavage fluids stimulate NIH3T3 fibroblast proliferation and contain increased tumour necrosis factor and IL-6 in experimental silica-induced rat peritonitis, Clin Exp Immunol 1995; 100[1]: 139-144